http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine
-
MilliporeSigma Announces $65 Million Antibody-Drug Conjugate Manufacturing Expansion
-
/C O R R E C T I O N -- MilliporeSigma/
-
MilliporeSigma Opens its Largest M Lab™ Collaboration Center in Shanghai
-
FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma
-
MilliporeSigma and Baylor College of Medicine Collaborate to Advance a Vaccine Manufacturing Platform to Fight Covid-19
-
MilliporeSigma Granted U.S. Patents for Foundational CRISPR-Cas9 Technology
-
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO® for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
-
MilliporeSigma Awarded Second U.S. Patent for CRISPR Gene-Editing Technology
-
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
-
MilliporeSigma's New LANEXO™ System to Improve Scientists' Productivity in the Lab
-
EMD Serono, Pfizer (PFE) Announce BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
-
BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
-
MilliporeSigma Licenses Foundational CRISPR Integration Technology to Promega
-
Japan and Singapore Grant CRISPR Patents to MilliporeSigma
-
MilliporeSigma Licenses CRISPR Gene-Editing Technology to Evotec
-
EMD Serono, Pfizer (PFE) Provide Update on Phase III JAVELIN Gastric 100 Trial
-
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial
-
European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
-
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
-
Merck KGaA, Pfizer (PFE) Announce CHMP Adopts Positive Opinion for BAVENCIO Plus Axitinib for First-Line Treatment of Patients with Advanced RCC
-
CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
-
MilliporeSigma Granted 20 CRISPR Patents Total Worldwide
-
MilliporeSigma and Broad Institute Announce CRISPR License Framework to Encourage Innovation
-
Massachusetts-based Business Sectors of Merck KGaA, Darmstadt, Germany Named 'Best Places to Work' by Boston Business Journal
-
MilliporeSigma Joins TRANSVAC2 Program to Advance Vaccine Development and Manufacturing
-
FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma
-
MilliporeSigma Opens First M Lab™ Collaboration Center in Europe
-
MilliporeSigma to Collaborate with GenScript to Accelerate Cell and Gene Therapy Industrialization in China
-
MilliporeSigma Awarded Canadian CRISPR Nickase Patent for Foundational Genome-Editing Technology
-
MilliporeSigma Receives First U.S. Patent for Improved CRISPR Genome-Editing Method
-
Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine
-
EMD Seron, Pfizer (PFE) Announce FDA Accepted sBLA and Granted Priority Review for BAVENCIO Plus INLYTA for Treatment of Advanced RCC
-
FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma
-
UPDATE: Merck KGaA, Pfizer (PFE) to Terminate JAVELIN Ovarian 100 Trial of Avelumab
-
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer
-
MilliporeSigma and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent Models
-
MilliporeSigma Wins Two R&D 100 Awards for Innovation in 2018
-
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
-
MilliporeSigma Launches BioContinuum™ Platform for Next-Generation Process Improvements
-
MilliporeSigma Opens M Lab™ Collaboration Center in São Paulo, Brazil
-
BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study
-
Two-Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab)
-
Merck KGaA, Pfizer (PFE) Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced NSCLC
-
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
-
Merck (MRK) and Pfizer (PFE) Granted FDA Breakthrough Therapy Designation for Avelumab, INLYTA Combo in Advanced Renal Cell Carcinom
-
FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma
-
FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma
-
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients with Pre-Treated Advanced Gastric Cancer
-
Merck (MRK) and Pfizer (PFE) Announce Phase III JAVELIN Gastric 300 Study in Patients With Pre-Treated Advanced Gastric Cancer Did Not Meet Primary Endpoint
